Clinical Trials Sponsored by Qompium NV

Total 334 results

Galapagos NV

Completed

First-in-Human Single Ascending and Multiple Dose of GLPG0555

Healthy

Belgium
Galapagos NV

Recruiting

A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis (GALARISSO)

Dermatomyositis

United States, Belgium, Italy, Chile, Spain, Poland, United Kingdom, Bulgaria, Romania, Colombia, Croatia, Czechia, France, Argentina
Oystershell NV

Recruiting

A Clinical Trial to Evaluate Efficacy and Safety of a New Suffocating Head Lice Product.

Head Lice | Pediculosis Capitis

United States
Galapagos NV

Active, not recruiting

A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis (OLINGUITO)

Axial Spondyloarthritis

Belgium, Korea, Republic of, Greece, Taiwan, France, Romania, Germany, Netherlands, Italy, Philippines, United Kingdom, Hungary, Estonia, South Africa, Bulgaria, Spain, Croatia, Czechia, Poland, Lithuania
Galapagos NV

Active, not recruiting

Prospective Observational Study of Filgotinib in Participants With Rheumatoid Arthritis in France (PARROTFISH)

Rheumatoid Arthritis

France
Oystershell NV

Completed

Safety and Efficacy of a Head Lice Shampoo

Head Lice

Germany
Oystershell NV

Completed

Efficacy and Safety of a Medical Device for the Treatment of Toenail Onychomycosis

Onychomycosis of Toenail

Tunisia
Galapagos NV

Completed

Relative Bioavailability and Effect of Food Study With an Oral Mini-tablet Formulation of Filgotinib in Healthy Subjects

Bioavailability

Canada
Galapagos NV

Terminated

A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS) (GLIDER)

Primary Sjögren Syndrome

Germany, Greece, Poland, Hungary, Ukraine
Galapagos NV

Terminated

A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Autosomal Dominant Polycystic Kidney Disease

Belgium, Netherlands, Italy, Spain, Czechia, Germany, Poland
Galapagos NV

Completed

Drug-drug Interaction Study With GLPG3667 and Itraconazole in Healthy Subjects

Healthy

Canada
Galapagos NV

Terminated

An Open-label, Long-term Extension Study With Filgotinib in Active Psoriatic Arthritis.

Psoriatic Arthritis

Estonia, Belgium, Bulgaria, Czechia, Poland, Spain, Ukraine
Galapagos NV

Terminated

A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis

Systemic Sclerosis

Spain, United States, Belgium, United Kingdom, Italy
Galapagos NV

Completed

A Study to Evaluate How Well Single and Multiple Doses of GLPG3667 Are Tolerated in Healthy, Adult Subjects

Healthy

Belgium
Galapagos NV

Completed

Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects

Healthy

Canada
Galapagos NV

Terminated

A Study Evaluating the Effects of GLPG3970 Given as Oral Treatment for 12 Weeks in Adults With Systemic Lupus Erythematosus (TAPINOMA)

Systemic Lupus Erythematosus

Spain, Bulgaria, Moldova, Republic of, Poland, Ukraine
Galapagos NV

Completed

Drug-drug Interaction Study With GLPG3970 and Sulfasalazine in Adult, Healthy Subjects

Healthy

United States
Galapagos NV

Completed

A Study Evaluating the Effects of GLPG3667 Given as an Oral Treatment for 4 Weeks in Adults With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

Poland, Slovakia, Bulgaria
Galapagos NV

Terminated

A Study in Healthy Male Volunteers Investigating the Safety, Absorption and Elimination of Single Doses of GLPG4059

Healthy

Netherlands
Galapagos NV

Completed

A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis (NOVESA)

Systemic Sclerosis

United States, Belgium, Spain, Germany, United Kingdom, Italy
Ectosense NV

Completed

A Validation Study of the NightOwl PAT-based Home Sleep Apnea Test

Sleep Apnea

United States
Galapagos NV

Completed

A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3667

Healthy

Belgium
Barco NV

Completed

Development and Validation of a New Digital Dermatoscope in the United States

Skin Cancer

United States
Galapagos NV

Terminated

A Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics (PK)/Pharmacodynamics (PD) of MOR106 in Subjects With Moderate to Severe Atopic Dermatitis (IGUANA)

Atopic Dermatitis

Germany, Hungary, Poland, Slovakia, United Kingdom
Galapagos NV

Completed

A Study to Assess Efficacy and Safety of Filgotinib in Ankylosing Spondylitis (TORTUGA)

Ankylosing Spondylitis

Belgium, Bulgaria, Czechia, Estonia, Poland, Spain, Ukraine
Galapagos NV

Completed

A Study in Healthy Male Volunteers to Look at How the Test Medicine GLPG1690 is Taken up by the Body When Doses of Itraconazole and Voriconazole Are Given to Healthy Volunteers

Healthy

United Kingdom
Galapagos NV

Completed

GLPG2737 on Top of Orkambi in Subjects With Cystic Fibrosis (PELICAN)

Cystic Fibrosis

Germany
Galapagos NV

Completed

A Study to Assess Efficacy and Safety of Filgotinib in Active Psoriatic Arthritis (EQUATOR)

Psoriatic Arthritis

Estonia, Belgium, Bulgaria, Czechia, Poland, Spain, Ukraine
FLUIDDA nv

Terminated

Prospective Study for Transplant Optimization Using Functional Imaging (TROFI)

Bronchiolitis Obliterans | Lung Transplant Rejection

Belgium
Galapagos NV

Completed

Pharmacokinetics of GLPG2737 in Male Subjects With Cystic Fibrosis

Cystic Fibrosis

Belgium
Galapagos NV

Completed

A Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic Fibrosis

Cystic Fibrosis

Ireland, United Kingdom, Belgium, Australia, Czechia, Germany
FLUIDDA nv

Completed

Study to Assess the Effect of the Aerobika Device in Addition to Standard of Care Treatment in Sputum Producing COPD Patients Using FRI

Pulmonary Disease, Chronic Obstructive | COPD

Belgium
Novosanis NV

Completed

Echographic Measurement of Skin Thickness in Children (PIDIC-1)

Skin Thickness

Belgium
Galapagos NV

Completed

Study to Compare Bioavailability of GLPG1972 Given as 2 Different Tablet Formulations Versus an Oral Solution

Healthy

Belgium
FLUIDDA nv

Completed

Transplant Optimization Using Functional Imaging (TROFI)

Bronchiolitis Obliterans | Lung Transplant Rejection

United States
Galapagos NV

Completed

Study of GLPG1837 in Subjects With Cystic Fibrosis (G551D Mutation) (SAPHIRA1)

Cystic Fibrosis

United Kingdom, Australia, Ireland, Germany, Czech Republic
Galapagos NV

Completed

Study of GLPG1837 in Subjects With Cystic Fibrosis (S1251N Mutation) (SAPHIRA2)

Cystic Fibrosis

Belgium, Netherlands
Galapagos NV

Completed

Oral Bioavailability of Solid Formulation of GLPG1837 With and Without Food

Healthy

Belgium
Galapagos NV

Completed

First-in-Human Single and Multiple Dose of GLPG1690

Healthy

Belgium
Amakem, NV

Completed

A Single Centre Study to Evaluate 3 Ophthalmic Formulations in Healthy Subjects

Ocular Hypertension | Glaucoma | Eye Disease

United Kingdom
Galapagos NV

Completed

Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of GLPG0974 in Subjects With Ulcerative Colitis

Ulcerative Colitis

Belgium, Czech Republic, Slovakia, Latvia
FLUIDDA nv

Terminated

Long-term Effects of Non-invasive Ventilation in Hypercapnic Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease

Netherlands, Belgium
Amakem, NV

Completed

Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma

Ocular Hypertension | Glaucoma | Eye Disease

United States
Galapagos NV

Completed

Multiple Ascending Dose Study of GLPG0974 in Healthy Subjects

Healthy

Belgium
FLUIDDA nv

Completed

Clinical Study to Assess Change in Upper Airway Geometry Between Upright and Supine Position

Changes in Upper Airway Geometry

Belgium
Galapagos NV

Completed

First-in-Human Exploratory Single Ascending Dose of GLPG0974

Healthy

Belgium
Galapagos NV

Completed

GLPG0259 Multiple Ascending Dose and Methotrexate Drug-drug Interaction (DDI) in Healthy Subjects

Healthy

Belgium
Galapagos NV

Completed

GLPG0778: Multiple Ascending Oral Doses, Pharmacokinetic, Safety, and Pharmacodynamic Study

Healthy

Belgium
Galapagos NV

Completed

GLPG0259 in Methotrexate-refractory Rheumatoid Arthritis

Rheumatoid Arthritis

Belgium, Netherlands, Poland, Russian Federation, Ukraine
Galapagos NV

Completed

Oral Bioavailability of Two Solid Formulations of GLPG0259.

Healthy

Belgium

3

Subscribe